Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Intervalo de año de publicación
1.
Int Immunopharmacol ; 7(5): 625-36, 2007 May.
Artículo en Inglés | MEDLINE | ID: mdl-17386410

RESUMEN

Plants constitute an important source of compounds which can induce apoptosis in a variety of cells. Previously, we reported the isolation of a trypsin inhibitor from Peltophorum dubium seeds (PDTI). This inhibitor, as well as soybean trypsin inhibitor (SBTI), both belonging to the Kunitz family, have lectin-like properties and trigger rat lymphoma cell apoptosis. In the present study, we demonstrate for the first time that PDTI and SBTI induce human leukemia Jurkat cell death. Induction of apoptosis was confirmed by flow cytometry after propidium iodide labeling of apoptotic nuclei, showing a considerable increase of the sub G(0)/G(1) fraction, with no cell cycle arrest. With the purpose of gaining insight into the signaling pathways involved, we investigated the activation of caspases and the effect of caspase inhibitors, and showed caspases-3 and -8-like activation by PDTI or SBTI-treatment. Consistent with these results, pan caspase inhibitor and caspase-8 inhibitor protected Jurkat cells from apoptosis. However, there was no caspase-9 activation, confirmed by the failure of caspase-9 inhibitor to prevent cell death. No significant release of cytochrome c from mitochondria was detected suggesting that the intrinsic mitochondrial pathway is not predominant in the apoptotic process. On the other hand, recruitment of Fas-associated death domain (FADD) to the cell membrane indicates the involvement of this adaptor protein in PDTI- and SBTI-induced apoptosis in Jurkat cells. Furthermore, human peripheral lymphocytes, either stimulated with phytohemagglutinin or not, are also susceptible to viability decrease induced by these inhibitors.


Asunto(s)
Apoptosis/efectos de los fármacos , Fabaceae/química , Inhibidor de la Tripsina de Soja de Kunitz/farmacología , Inhibidores de Tripsina/farmacología , Inhibidores de Caspasas , Caspasas/metabolismo , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Citocromos c/metabolismo , Citosol/efectos de los fármacos , Citosol/enzimología , Fragmentación del ADN/efectos de los fármacos , Activación Enzimática/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Proteína de Dominio de Muerte Asociada a Fas/metabolismo , Células HeLa , Humanos , Técnicas In Vitro , Células Jurkat , Linfocitos/efectos de los fármacos , Mitocondrias/enzimología , Fitohemaglutininas/farmacología , Semillas/química , Transducción de Señal/efectos de los fármacos
2.
Glycobiology ; 16(9): 810-21, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16769778

RESUMEN

Galectin-1 (Gal-1) is a widely expressed beta-galactoside-binding protein that exerts pleiotropic biological functions. To gain insight into the potential role of Gal-1 as a novel modulator of Leydig cells, we investigated its effect on the growth and death of MA-10 tumor Leydig cells. In this study, we identified cytoplasmic Gal-1 expression in these tumor cells by cytofluorometry. DNA fragmentation, caspase-3, -8, and -9 activation, loss of mitochondrial membrane potential (DeltaPsim), cytochrome c (Cyt c) release, and FasL expression suggested that relatively high concentrations of exogenously added recombinant Gal-1 (rGal-1) induced apoptosis by the mitochondrial and death receptor pathways. These pathways were independently activated, as the presence of the inhibitor of caspase-8 or -9 only partially prevented Gal-1-effect. On the contrary, low concentrations of Gal-1 significantly promoted cell proliferation, without inducing cell death. Importantly, the presence of the disaccharide lactose prevented Gal-1 effects, suggesting the involvement of the carbohydrate recognition domain (CRD). This study provides strong evidence that Gal-1 is a novel biphasic regulator of Leydig tumor cell number, suggesting a novel role for Gal-1 in the reproductive physiopathology.


Asunto(s)
Galectina 1/farmacología , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Células Intersticiales del Testículo/metabolismo , Proteínas de Neoplasias/biosíntesis , Tumor de Células de Sertoli-Leydig/metabolismo , Neoplasias Testiculares/metabolismo , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Citoplasma/metabolismo , Citoplasma/patología , Fragmentación del ADN/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Galectina 1/biosíntesis , Humanos , Lactosa/farmacología , Células Intersticiales del Testículo/patología , Masculino , Potenciales de la Membrana/efectos de los fármacos , Mitocondrias/metabolismo , Mitocondrias/patología , Tumor de Células de Sertoli-Leydig/patología , Neoplasias Testiculares/patología
3.
Arch Biochem Biophys ; 416(2): 249-56, 2003 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-12893303

RESUMEN

Nitric oxide (NO) is an important modulator involved in immune regulation. Here, we describe conditions under which NO-donors induce apoptosis on Nb2 lymphoma cells, as evidenced by decreased cell viability and increased hypodiploid DNA content determined by flow cytometry. In addition, DNA fragmentation typical of apoptosis was shown by agarose gel electrophoresis. This apoptosis was accompanied by a significant increase of caspase-3-like enzymatic activity. Both ovine prolactin (oPRL) and ovine placental lactogen (oPL) exerted a protective effect on the NO-donor-induced apoptosis. Furthermore, dexamethasone (Dex)-induced cell death was also associated with caspase-3-like activity and oPL had the same potency as oPRL in its protective effect on Dex-induced apoptosis of Nb2 cells.


Asunto(s)
Apoptosis/efectos de los fármacos , Linfoma/fisiopatología , Óxido Nítrico/metabolismo , Lactógeno Placentario/farmacología , Prolactina/farmacología , Animales , Caspasa 3 , Caspasas/biosíntesis , Bovinos , Supervivencia Celular/efectos de los fármacos , Fragmentación del ADN/efectos de los fármacos , Dexametasona/farmacología , Diploidia , Linfoma/enzimología , Linfoma/genética , Linfoma/metabolismo , Sustancias Protectoras/farmacología , Ratas , Células Tumorales Cultivadas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA